HHS to invest in domestic production of essential medical supplies
President Biden will issue a determination that gives the Department of Health and Human Services broader authority to invest in domestic manufacturing of essential medicines and medical countermeasures under Title III of the Defense Production Act, the White House announced Nov. 27 as it convened the first meeting of the White House Council on Supply Chain Resilience. Among other actions, HHS will invest $35 million to domestically produce key starting materials for sterile injectable medicines and designate someone to coordinate efforts to strengthen supply chain resilience, while the Department of Defense will soon release a report on strengthening pharmaceutical supply chain resilience, the Administration said.
Related News Articles
Headline
The Department of Health and Human Services’ Administration for Strategic Preparedness and Response June 5 announced it selected two locations to test an…
Headline
The U.S. Court of International Trade May 28 blocked a series of tariffs issued by the Trump administration under the International Emergency Economic Powers…
Chairperson's File
We are all closely watching changing tariff policy as it raises serious considerations for the medical products, devices and pharmaceuticals supply chain. Our…
Chairperson's File
Most hospitals and health systems are the largest organizations in our communities, providing critical services needed by every one of our neighbors. We take…
Headline
The AHA May 16 urged the Department of Commerce to consider tariff exceptions for critical minerals and derivative products used for medical purposes. Critical…
Headline
The AHA May 14 urged the Senate Finance Committee to take steps to strengthen the supply chain for essential pharmaceutical and other medical products. In…